Loading
A phase 1/2 trial of SPH4336 and Cadonilimab in advanced solid tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT05944224 by Shanghai Pharmaceuticals Holding Co., Ltd, with 63 participants planned, started 2023-10-17 and due to reach its primary completion in 2026-12-31. Interventions recorded: SPH4336 and Cadonilimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SPH4336, GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares GenFleet Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/